Two cases of psoriasis responding to erlotinib: Time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?

Dermatology

Volumn 225, Issue 2, 2012, Pages 179-182

  Overbeck, Tobias R ^a,b   Griesinger, Frank ^a  

^a PIUS HOSPITAL   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Epidermal growth factor receptors; Erlotinib; Lung cancer; Psoriasis; Tyrosine kinase inhibitors

Indexed keywords

BETAMETHASONE; CALCIPOTRIOL; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ICHTHAMMOL; KERATOLYTIC AGENT; ZINC OXIDE;

ADULT; AGED; BALNEOTHERAPY; BODY RASH; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CASE REPORT; COMPASSIONATE USE; CORTICOSTEROID THERAPY; DESQUAMATION; DRUG DOSE REDUCTION; ELBOW; FAMILY HISTORY; FEMALE; HUMAN; LOCAL THERAPY; LUNG NON SMALL CELL CANCER; MALE; PHOTOTHERAPY; POINT MUTATION; PRIORITY JOURNAL; PSORIASIS; RECURRENT CANCER; REVIEW; SKIN DEFECT; TREATMENT RESPONSE; ULTRAVIOLET IRRADIATION;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PSORIASIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84870795560     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000342786     Document Type: Review

References (21)

1. King LE Jr, Gates RE, Stoscheck CM, Nanney LB: The EGF/TGF alpha receptor in skin. J Invest Dermatol 1990; 94(6 suppl):164S-170S.
2. Nanney LB, Stoscheck CM, Magid M, King LE Jr: Altered [ 125 I]epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 1986; 86: 260-265.
3. Ben Bassat H: Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy. Curr Opin Investig Drugs 2001; 2: 1539-1545.
4. Trivin F, Boucher E, Raoul JL: Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy. Acta Oncol 2004; 43: 592-593.
5. van Ruissen F, de Jongh GJ, van Erp PE, Boezeman JB, Schalkwijk J: Cell kinetic characterization of cultured human keratinocytes from normal and psoriatic individuals. J Cell Physiol 1996; 168: 684-694.
6. King LE Jr, Gates RE, Stoscheck CM, Nanney LB: Epidermal growth factor/transforming growth factor alpha receptors and psoriasis. J Invest Dermatol 1990; 95: 10S-12S.
7. Ben Bassat H, Levitzki A: Inhibitors of tyrosine kinases in the treatment of psoriasis. Isr Med Assoc J 2000; 2(suppl):69-73.
8. Mermelstein FH, Abidi TF, Laskin JD: Inhibition of epidermal growth factor receptor tyrosine kinase activity in A431 human epidermoid cells following psoralen/ultraviolet light treatment. Mol Pharmacol 1989; 36: 848-855.
9. Powell TJ, Ben Bassat H, Klein BY, et al: Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol 1999; 141: 802-810.
10. Varani J, Kang S, Stoll S, Elder JT: Human psoriatic skin in organ culture: comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor. Pathobiology 1998; 66: 253-259.
11. Zorzou MP, Stratigos A, Efstathiou E, Bamias A: Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta Derm Venereol 2004; 84: 308-309.
12. Giroux LE, Friard S, Couderc LJ: Improvement of psoriasis in a lung cancer patient treated with erlotinib. Eur J Dermatol 2010; 20: 243-244.
13. Narayanan S, Callis-Duffin K, Batten J, Agarwal N: Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci 2010; 339: 580-581.
14. Keshtgarpour M, Dudek AZ: SU-011248, a vascular endothelial growth factor receptortyrosine kinase inhibitor, controls chronic psoriasis. Transl Res 2007; 149: 103-106.
15. Fournier C, Tisman G: Sorafenib-associated remission of psoriasis in hypernephroma: case report. Dermatol Online J 2010; 16: 17. 16
16. Halin C, Fahrngruber H, Meingassner JG, et al: Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 2008; 173: 265-277.
17. Wierzbicka E, Tourani JM, Guillet G: Improvement of psoriasis and cutaneous sideeffects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis? Br J Dermatol 2006; 155: 213-214.
18. Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y: Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour. Br J Dermatol 2002; 147: 406-407.
19. Wrone-Smith T, Nickoloff BJ: Dermal Injection of immunocytes induces psoriasis. J Clin Invest 1996; 98: 1878-1887.
20. Mascia F, Mariani V, Girolomoni G, Pastore S: Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163: 303-312.
21. Khetarpal VK, Markham PM, Ziemniak JA: Dispositional characteristics of a tyrosine kinase inhibitor (RG 14620) in rats and rabbits following intravenous administration or dermal application. Drug Metab Dispos 1994; 22: 216-223.